Back to Archived News
Lifeline Biotechnologies, Inc. Prepares Patent Filing for Improved First Warning™ Diagnostic System
Tuesday, June 10, 2008
Reno, NV -- Lifeline Biotechnologies, Inc. (OTCPK: LLBT), a developer of innovative medical technology, today announced that it has begun preparation of a provisional patent on a new neural network diagnostic system after a five-year developmental period. As previously announced, Lifeline has been working diligently with a prominent Asian university to further develop and enhance the company's First Warning System™. This pending patent is the result of that extensive work.
Jim Holmes, Lifeline’s CEO, stated, "This effort represents extensive collaboration between Lifeline Biotechnology and two university professors who are renowned experts in thermal analysis and biotechnology. The new system utilizes five different types of neural networks in tandem, a technique which has never been used to untangle the thermal information collected by the First Warning System™."
According to Dr. Louis Keith, Emeritus Professor of Obstetrics and Gynecology at the Feinberg School of Medicine at Northwestern University, "We can now determine which of the benign lesions the First Warning detects has the potential of becoming cancer. Using a combination of five neural network constructions, we have broken this elusive barrier. This new system has the ability to provide us with 100% selectivity, finding all lesions in the breast and with specificity in the low nineties, correctly classifying all tumors. This system will continue to improve in its accuracy because it learns with each new case presented to it."
Holmes also added, "After our provisional patent is filed, we will begin a search for a strategic partner."
About Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System™, which is designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: development of the First Warning System™’s interpretive, proprietary software, clinical trials and FDA pre-marketing clearance. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive. www.lbti.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, successful development of the Company’s product and regulatory and shareholder approval for anticipated actions.
Back to Archived News
